AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 192 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 1.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $276,000 | -16.4% | 6,000 | 0.0% | 0.02% | -15.4% |
| Q2 2021 | $330,000 | +6.8% | 6,000 | 0.0% | 0.03% | 0.0% |
| Q1 2021 | $309,000 | +34.9% | 6,000 | +76.5% | 0.03% | +4.0% |
| Q1 2019 | $229,000 | -12.6% | 3,400 | 0.0% | 0.02% | -13.8% |
| Q3 2018 | $262,000 | -8.4% | 3,400 | 0.0% | 0.03% | -14.7% |
| Q2 2018 | $286,000 | +2.9% | 3,400 | 0.0% | 0.03% | -2.9% |
| Q1 2018 | $278,000 | +22.5% | 3,400 | 0.0% | 0.04% | +20.7% |
| Q3 2017 | $227,000 | +2.7% | 3,400 | 0.0% | 0.03% | -21.6% |
| Q4 2015 | $221,000 | -7.9% | 3,400 | 0.0% | 0.04% | -9.8% |
| Q3 2015 | $240,000 | -36.5% | 3,400 | 0.0% | 0.04% | -25.5% |
| Q2 2015 | $378,000 | +17.8% | 3,400 | 0.0% | 0.06% | +19.6% |
| Q1 2015 | $321,000 | -22.7% | 3,400 | -8.1% | 0.05% | -23.3% |
| Q4 2014 | $415,000 | +35.2% | 3,700 | -26.0% | 0.06% | +27.7% |
| Q3 2014 | $307,000 | +34.1% | 5,000 | 0.0% | 0.05% | +46.9% |
| Q2 2014 | $229,000 | – | 5,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Ventures 2007 General Partner LLC | 1,930,369 | $118,428,000 | 83.56% |
| Third Rock Ventures, LLC | 3,070,090 | $188,350,000 | 21.97% |
| Opaleye Management Inc. | 113,500 | $6,963,225,000 | 5.43% |
| BB BIOTECH AG | 1,890,521 | $115,983,000 | 4.72% |
| Eventide Asset Management | 431,600 | $26,479,000 | 3.70% |
| Atika Capital Management LLC | 54,000 | $3,313,000 | 2.55% |
| Cormorant Asset Management, LP | 100,000 | $6,135,000 | 1.26% |
| BRIDGER MANAGEMENT, LLC | 220,099 | $13,503,000 | 0.92% |
| Ghost Tree Capital, LLC | 20,000 | $1,227,000 | 0.67% |
| HAMILTON LANE ADVISORS LLC | 27,544 | $1,690,000 | 0.55% |